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Abstract
Introduction:  If left untreated, severe combined immunodeficiency can lead to an acute
susceptibility to infection. The intrauterine environment is sterile until the amniotic membranes
rupture. The vaginal flora then ascends into the genital tract, thus increasing the risk of
chorioamnionitis. An extremely premature and prolonged membrane rupture is associated with a
dismal prognosis for an immunocompetent preterm fetus. There are no case reports to date that
detail the outcome of an immunocompromised preterm baby following prolonged rupture of
membranes.
Case presentation: We present the case of a 32-year-old Indian woman who delivered a 31-
week gestational baby who had a severe combined immunodeficiency following premature
prelabour prolonged rupture of the membranes at the 14th week of gestation.
Conclusion: Extreme preterm prelabour spontaneous rupture of membranes in an underlying
condition of severe combined immunodeficiency does not necessarily lead to an unfavourable
outcome.
Introduction
Severe combined immunodeficiency (SCID) is a com-
bined cellular and humoral immunodeficiency resulting
from a lack of functional T and B lymphocytes. In some
cases, SCID is also combined with a deficiency of natural
killer cells. This condition is extremely rare, affecting
approximately only 1 in 100,000 live births. SCID is usu-
ally diagnosed after the 3rd month of gestation, during the
onset of one or more serious infections such as recurrent
or persistent infections despite conventional treatment,
infections with opportunistic organisms such as Pneumo-
cystis, and a failure to thrive. SCID is usually X-linked and
can be diagnosed through genetic testing.
Babies in general are more susceptible to infections as
compared to adults. This susceptibility is even more pro-
nounced in preterm babies and those who have been
potentially exposed to maternal flora following a breach
in the amniotic membrane due to a prolonged prelabour
spontaneous rupture of the membranes (SROM). Patho-
gens gaining entry into the baby's system through the
mucosa of the respiratory and gastrointestinal tracts are
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poorly localised. The preterm baby can thus easily become
systemically unwell.
The sterile environment of the intrauterine amniotic sac
limits the need for learned immune responses to specific
antigens prior to birth. Upon birth, a normal baby has
some immunoglobulins (Ig), with IgG as predominant
because it is small enough to cross the placenta and be
transferred from the mother. The level of IgG at birth is
similar to that of the mother and provides passive immu-
nity to mainly viral infections in the first few months of
life.
Meanwhile, IgM and IgA do not cross the placental barrier
but are produced by the normal fetus in utero from
approximately 28 weeks of gestation. Levels of IgM at term
are 20% of those present in adults, unless intrauterine
infection develops and the fetus mounts an immune
response to further elevate IgM levels. IgM provides a
degree of protection to the neonate from enteric infec-
tions. While IgA levels are very low at birth, its production
increases rapidly following delivery to reach adult values
within two months. IgA protects against infection of the
respiratory tract, the gastrointestinal tract and the eyes.
The levels of both IgM and IgG at birth are lower in pre-
term than in term neonates [1].
There is no effect to the immune function of a female car-
rier of X-linked SCID. Thus, the fetus of such a woman
generally has normal IgG levels in utero and at birth.
The prognosis for a normal pregnancy where the mem-
branes rupture at 14 weeks is dismal due primarily to the
risk of miscarriage secondary to infection. Even with
appropriate treatment, approximately 50% of pregnancies
are delivered each subsequent week following preterm
SROM. Therefore, when the membranes rupture before 20
weeks of gestation the probability of reaching viability is
<5% [2].
A second reason for dismal prognosis is the risk of neona-
tal death secondary to pulmonary hypoplasia when preg-
nancy becomes viable. The chance of pulmonary
hypoplasia is lessened if the fluid re-accumulates before
24 weeks of gestation. One study using a multivariate
analysis suggested that the likelihood for neonate survival
increases by 2.7 (95% CI 1.45 to 4.65) for every 5-mm
increase in the depth of amniotic fluid during the follow-
up from rupture up to the 24th week of gestation [3].
Despite dismal prognosis, however, expectant manage-
ment for preterm SROM at 14 weeks may be appropriate
if the mother is well-informed of the risks for the neonate.
The conclusions of the ORACLE trials [4,5] indicated that
a course of oral erythromycin is the antibiotic of choice in
the treatment of expectantly managed preterm SROM.
This is because erythromycin is associated with a reduc-
tion in neonatal infection, slight prolongation of preg-
nancy with no increase in the likelihood of developing
necrotising enterocolitis. Based on evidence from a study
of preterm SROM conducted by the Maternal-Fetal Medi-
cine Units of the National Institute of Child Health and
Human Development, 7 days of antibiotics should be pre-
scribed because longer courses have not been shown to be
more effective and may actually promote antibiotic resist-
ance [6].
Maternal protein C deficiency is associated with an
increased risk of poor pregnancy outcome including mis-
carriage, stillbirth and preterm delivery.
Case presentation
A 32-year-old Indian woman presented to our gynaecol-
ogy clinic with secondary subfertility. Routine screening
found her to be positive for protein C deficiency. In 1999,
the woman had previously delivered a son by elective cae-
sarean section following a diagnosis of transverse lie at 39
weeks of gestation. The baby was subsequently diagnosed
with SCID and died at 8 months due to this condition. A
specialist genetic centre indicated that this was an X-
linked condition and the woman is a carrier of the muta-
tion c.283G>A (W90X) in exon 2 of her IL2RγC gene.
She was advised of a 50%-risk of any subsequent male off-
spring being affected by SCID and was thus offered preim-
plantation genetic diagnosis. However she subsequently
conceived the index pregnancy spontaneously. She was
commenced on aspirin, low molecular weight heparin
(LMWH) and progesterone pessaries as soon as the preg-
nancy was confirmed by ultrasound at 6 weeks. Resutls of
her nuchal translucency screening and first trimester
anomaly scan were normal.
The woman presented with leakage of liquor at 14+5 weeks
gestation. Spontaneous rupture of the membranes was
confirmed clinically and through an ultrasonography. She
was commenced on antibiotic prophylaxis with oral
erythromycin and her medication of progesterone pessa-
ries was discontinued. Serial specialist ultrasonography at
16, 18, 20 and 22 weeks confirmed a normally grown
male fetus with no obvious structural defects. The pla-
centa was posterior and low, and the severe oligohydram-
nios was persistent. In view of the oligohydramnios due to
extreme preterm SROM, an invasive genetic testing was
not felt to be appropriate. The risk of this male fetus being
affected with SCID therefore remained at 50%. Because of
the extremely poor prognosis for the baby, the couple was
offered a termination of pregnancy but they declined. The
pregnancy continued, septic markers remained negative,Journal of Medical Case Reports 2009, 3:118 http://www.jmedicalcasereports.com/content/3/1/118
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and she remained on continuous oral erythromycin, aspi-
rin and LMWH.
At 24+4 weeks gestation, the woman self-referred with a
history of unprovoked vaginal bleeding. She was given
dexamethasone and was transferred to a centre with Level
1 neonatal facilities. She stayed at the centre until her
transfer back to her local hospital at 28+5. Erythromycin
was discontinued at 25+6 weeks gestation, maternal clini-
cal and laboratory signs of infection remained absent, and
ultrasound scan at 28 weeks showed normal growth of the
fetus and an amniotic fluid index of 8.4 cm. Upon
readmission, she was recommenced on erythromycin and
discharged from the hospital. She was advised instead to
visit the antenatal day unit twice a week for regular assess-
ments.
The woman remained stable until she presented again at
31+4  weeks with lower abdominal pain and recurrent
slight vaginal bleeding. It was found that her cervix was
dilating and that the baby's presentation was breech. An
emergency caesarean section was thus performed under
spinal anaesthetic. She made a good postoperative recov-
ery and was discharged after 5 days.
The baby boy was born with Apgar scores of 61 and 105
minutes and weighed 1830 g (50th  percentile). He
required some initial resuscitation but was transferred to
our special care baby unit with spontaneous respiratory
effort in facial oxygen. His white cell count and C-reactive
protein level were within the normal range (6.3 and <5,
respectively) while his blood cultures were negative at
birth. The baby was treated with oral nystatin, intravenous
benzyl penicillin and gentamicin. Isolation and barrier
nursing was also advised.
X-linked SCID (consistent with the mother's carrier type)
was confirmed by genetics testing during the neonatal
period. He received intravenous therapy of 1 g immu-
noglobulin on Day 3 and was transferred to a specialist
paediatric centre on Day 6. The baby underwent an
unconditioned CD34-selected mismatched family donor
bone marrow transplant (from his father) on Day 46. He
continued to receive monthly 2 g intravenous immu-
noglobulin and regular outpatient specialist paediatric
immunology reviews. As of this writing, the baby is thriv-
ing and still breastfeeding at 1 year of life. He is also show-
ing a good response to his treatment.
Discussion
Fetuses affected by SCID have significantly lower levels of
IgM and IgA at birth compared to gestationally age-
matched immunocompetent babies. It is thus likely that
SCID affected babies will be unable to mount any IgA and
IgG immune response in utero in response to ascending
infection as a result of SROM. As immunocompetent pre-
mature babies produce such a poor response in utero, the
question is whether SCID affected babies in a condition of
preterm SROM have a higher risk of in utero infection than
those who do not have SCID.
Conclusion
This baby was born in good condition and is currently
thriving and living a normal life. This unusual case of
adverse prognostic factors, including an underlying
genetic condition, prelabour preterm SROM and maternal
protein C deficiency, demonstrates that the outcome for
babies with this condition is not necessarily hopeless.
This baby was born without evidence of in utero infection
despite the expected poor prognosis of having premature
prelabour SROM from 14+ weeks. Had an infection
occurred, the prognosis would have been certainly poor.
However, this would not be as a result of the SCID condi-
tion, and the baby would have had normal levels of IgG at
birth because of transplacental transfer from his mother.
Because normal babies have a poor IgA and IgM immune
response in utero at 31 weeks, it is very unlikely that the
inability to mount any IgA or IgM response because of the
SCID condition had any effect on the outcome in this
case. It is therefore reasonable to conclude that the in utero
management of fetuses with known or suspected primary
congenital immunodeficiency including SCID should not
be managed any differently than preterm prelabour
SROM in normal pregnancies.
The counselling of parents regarding the possible progno-
sis following a diagnosis of SROM at extreme prematurity
should not be altered if the baby is known or suspected to
be affected with SCID. With regard to the antenatal use of
antibiotics in babies with SCID, the standard dose and
duration of treatment of erythromycin 250 mg 4 times
daily for 7 days should be prescribed. Measures to discour-
age ascending infection such as the avoidance of vaginal
examinations and sexual intercourse should be advised
regardless of an underlying diagnosis of SCID.
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